These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 33771722

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
    Buhl R, Tanase AM, Hosoe M, Cao W, Demin I, Bartels C, Jauernig J, Ziegler D, Patalano F, Hederer B, Kanniess F, Tillmann HC.
    Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS, Khindri S, Calder N, Machineni S, Hara H, Majumdar T, Febbraro S, Fuhr R, Woessner R.
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S, Vaidya S, Tillmann HC, Sakita Y, Machineni S, Heudi O, Furihata K.
    BMC Pulm Med; 2021 Jan 07; 21(1):18. PubMed ID: 33413291
    [Abstract] [Full Text] [Related]

  • 9. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
    Vaidya SS, Khindri S, Maahs S, Machineni S, Hara H, Juan A, Kaiser G.
    Clin Pharmacol Drug Dev; 2016 Jul 07; 5(4):285-95. PubMed ID: 27310329
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
    Kosoglou T, Hubbell J, Xuan F, Cutler DL, Meehan AG, Kantesaria B, Wittmer BA.
    Int J Chron Obstruct Pulmon Dis; 2013 Jul 07; 8():107-16. PubMed ID: 23525511
    [Abstract] [Full Text] [Related]

  • 11. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
    Daley-Yates PT, Deans A, Mehta R, Sousa AR.
    Pulm Pharmacol Ther; 2022 Dec 07; 77():102171. PubMed ID: 36243386
    [Abstract] [Full Text] [Related]

  • 12. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct 07; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 13. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
    Beasley RW, Donohue JF, Mehta R, Nelson HS, Clay M, Moton A, Kim HJ, Hederer BM.
    BMJ Open; 2015 Feb 03; 5(2):e006131. PubMed ID: 25649209
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O, Mucsi J, Kolosa N, Bandelli L, Sen B, Satlin LC, D'Andrea P.
    Respir Med; 2020 Jan 03; 161():105809. PubMed ID: 32056721
    [Abstract] [Full Text] [Related]

  • 15. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
    Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, Tillmann HC.
    Respir Res; 2020 Apr 15; 21(1):87. PubMed ID: 32295593
    [Abstract] [Full Text] [Related]

  • 16. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
    Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC.
    Adv Ther; 2022 Jun 15; 39(6):2365-2378. PubMed ID: 35072888
    [Abstract] [Full Text] [Related]

  • 17. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
    Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, Pfister P.
    Respir Med; 2020 Jun 15; 170():106021. PubMed ID: 32843164
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.